Maren Denison, third-year student at the University of Iowa, was in sixth grade when she found out her lung function had dropped to 60 percent as half of her lung had collapsed and was scarred shut.

One Lake Charles woman found her path was helping to find the cure for a deadly disease that took her husband.

Modulator therapy does not appear to affect the magnitude of lung function impairment or recovery pattern during pulmonary ...

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

Treatment with elexacaftor-tezacaftor-ivacaftor is associated with reduced levels of systemic inflammatory markers, which ...

Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer ...

NESS ZIONA, Israel - BiomX Inc. (NYSE American:PHGE), a micro-cap biotechnology company currently valued at $15.69 million with shares trading at $0.59, reported Friday that it has addressed FDA ...

Vertex Pharmaceuticals Inc. reported third-quarter sales that beat analysts’ expectations as the biotech company’s mainstay cystic fibrosis treatment saw revenue growth while new drugs’ performances ...

This study update could positively impact Vertex Pharmaceuticals and Moderna’s stock performance, as successful results may enhance their competitive position in the cystic fibrosis treatment market.

Baron Health Care Fund gained for the quarter and outperformed its benchmark, the Russell 3000 Health Care Index. Read more ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the third quarter.

Shares of Lexeo Therapeutics rose in off-hours trading after the company reported progress in discussions with the Food and Drug Administration regarding the accelerated approval pathway for its ...